Arvinas' oncology segment is focused on developing targeted protein degradation therapies for various cancers. This involves the discovery and development of PROTACs that selectively degrade proteins driving tumor growth and resistance to existing treatments. Key research areas include prostate cancer and breast cancer, with clinical trials evaluating the efficacy and safety of their lead compounds. The segment aims to improve patient outcomes by providing more effective and less toxic cancer treatments. Collaborations with pharmaceutical companies like Pfizer and Bayer are crucial for advancing clinical development and commercialization efforts. The focus is on addressing unmet needs in cancer therapy by targeting previously undruggable proteins and overcoming resistance mechanisms.

Arvinas' PROTAC (Proteolysis-Targeting Chimera) technology platform is the foundation of its drug discovery and development efforts. This platform leverages bifunctional molecules designed to bind both a target protein and an E3 ubiquitin ligase, leading to the ubiquitination and subsequent degradation of the target protein by the proteasome. The platform is highly versatile, allowing for the development of degraders against a wide range of disease-causing proteins. Research and development activities focus on optimizing PROTAC design, improving drug delivery, and expanding the range of targetable proteins. The technology has the potential to address previously undruggable targets and offer new therapeutic options for various diseases. Arvinas' collaborations with major pharmaceutical companies validate the potential of its PROTAC platform and accelerate the development of novel protein degradation therapies.